UCB entrusts Cimzia's psoriasis prospects to Dermira
This article was originally published in Scrip
UCB has licensed its rheumatoid arthritis drug Cimzia (certolizumab pegol) to Dermira, a private US dermatology company, with the aim of getting it approved as a treatment for psoriasis.
You may also be interested in...
UCB has reported positive data from the final Phase III trial of its anti-TNF product Cimzia in plaque psoriasis, paving the way for approval applications later this year, but the product will have to elbow its way into a competitive market already under the shadow of a biosimilar threat.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.